Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in areas of unmet medical need in the United States and internationally. The company has a market cap of $211.2 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.
GILD stock has rallied the broader market over the past year, surging 42.2% compared to the S&P 500 Index’s ($SPX) 10.3% surge. Moreover, in 2026, the stock has risen by nearly 38.8%, outperforming the SPX’s 10.2% rise.